HOME >> BIOLOGY >> NEWS
Cord Blood Registry achieves industry-leading stem cell recovery with new automation technology

San Bruno, CAFebruary 7, 2007Cord Blood Registry (CBR) today announced that it has completed initial validation testing of the company's proprietary CellAdvantageTM system using new automation technology for cell processing, developed by ThermoGenesis and distributed by GE Healthcare. The new technology, called the AXP AutoXpressTM Platform (AXPTM), is the industry's first functionally-closed, automated cord blood stem cell processing technology.

The FDA-required validation testing demonstrated that CBR's CellAdvantage system can meet or exceed the company's current mononuclear cell (MNC) -- or stem cell -- recovery rate of 98 percent, which is the highest published cell recovery rate in the industry. CBR will present data results at an upcoming medical meeting.

"Achieving these extremely high cell recovery rates through automation is a very significant advancement for our company and for the families we serve," said Tom Moore, chief executive officer of CBR. "Our business is experiencing dramatic growth as expectant parents increasingly choose to preserve their baby's cord blood stem cells with us. By integrating AXP automation technology into our CellAdvantage system, CBR is the only family bank that will be able to increase our cell processing capacity and at the same time maintain or exceed our industry-leading cell recovery rates."

Cord Blood Registry is the first and only family cord blood bank to adopt this cutting-edge technology and offer it to consumers who wish to cryopreserve their own genetically-related stem cells for future therapeutic use. The world's largest public donation bank, The New York Blood Center, has also adopted AXP processing.

"In our selection process, we closely evaluated the two automated cell processing systems available on the market, said Moore. "We determined that only AXP can deliver cell recovery rates that can exceed our current cell separation process and do so consistently."


'"/>

Contact: Elissa Armstrong
earmstrong@golinharris.com
312-729-4139
Golin/Harris International
7-Feb-2007


Page: 1 2

Related biology news :

1. Blood test may help signal tumors remission, return in throat cancer patients
2. Blood sugars manufacture limited by building blocks supply
3. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
4. Blood tests may be possible for mental health conditions
5. Blood test predicts cardiac events and death in heart patients
6. Blood clot fibers more elastic than spiders web
7. Blood-compatible nanoscale materials possible using heparin
8. Blood pressure medication may revolutionize treatment of Marfan syndrome
9. Blood levels of suspected carcinogen vary by race, ethnicity
10. Blood conservation strategies take center stage at Emory University Hospital forum
11. Blood test for colon cancer risk to be goal of Hopkins project

Post Your Comments:
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact ... products , in particular, drug/device combinations. The current system received a score of 0 ... for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. ... and patient recruitment services. The core expertise of PRC Clinical is focused on ...
(Date:7/29/2015)... ... 2015 , ... Asymmetrex, LLC founder and director ... full range of capabilities of its unique cache of technologies for identifying, quantifying, ... renewal and repair of normal tissues and organs. This property makes them the ...
(Date:7/28/2015)... ... , ... The new Xsample 530 sample changer for vials can be used with ... – from less than 12,000 mPas (internal air) up to 36,000 (external air) – and ... the eye about Xsample 530 is its removable magazine, which is easily lifted off its ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2
Cached News: